Larimar Therapeutics, Inc. (LRMR) Covered Calls

Larimar Therapeutics is a clinical-stage biotechnology company developing first-in-class treatments for complex rare diseases. Using a proprietary cell-penetrating peptide platform, the company’s lead candidate, nomlabofusp, delivers essential frataxin protein directly to the mitochondria to treat Friedreich’s ataxia. Larimar is dedicated to addressing the root cause of protein-deficiency diseases, aiming to improve clinical outcomes for patients with significant unmet medical needs.

You can sell covered calls on Larimar Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for LRMR (prices last updated Tue 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Larimar Therapeutics, Inc. (LRMR) is a biotechnology innovator focused on protein replacement therapies for rare, progressive neurodegenerative disorders. The company’s core technology utilizes a novel intracellular delivery platform to transport bioactive compounds across cell membranes. Its flagship program, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein designed to address Friedreich’s ataxia (FA) by restoring levels of frataxin, a mitochondrial protein whose deficiency leads to debilitating motor and sensory loss.

In February 2026, Larimar reached a pivotal regulatory milestone when the FDA granted Breakthrough Therapy Designation to nomlabofusp. This followed positive data from an open-label study showing that 100% of participants achieved skin frataxin levels similar to asymptomatic carriers. To fund its transition toward commercialization, Larimar completed a $100 million upsized public offering in late February 2026, extending its cash runway through the anticipated launch of its global Phase 3 confirmatory study.

Competitive Landscape

Larimar operates in the highly specialized orphan drug market, specifically targeting the $2 billion Friedreich’s ataxia sector. Its primary competitor is Biogen, which markets Skyclarys, the first FDA-approved treatment for FA. However, while Skyclarys is a small-molecule Nrf2 activator that treats symptoms, Larimar’s nomlabofusp is a direct protein replacement therapy that targets the disease’s underlying genetic cause.

The company also tracks against emerging genetic medicine firms such as Lexeo Therapeutics and PTC Therapeutics, which are developing gene therapies and small molecules for FA, respectively. Larimar’s competitive moat is built on its participation in the FDA’s START pilot program and its alignment with regulators on using skin frataxin as a surrogate endpoint for accelerated approval. This regulatory path potentially allows Larimar to reach the market years ahead of traditional clinical endpoints.

Strategic Outlook and Innovation

The strategic outlook for Larimar in 2026 is centered on its planned Biologics License Application (BLA) submission, targeted for June 2026. Following successful "START" program meetings, the company is focused on finalizing its data package seeking accelerated approval based on frataxin biomarkers. Innovation is also expanding into the "adolescent PK run-in" study, which aims to extend the therapeutic reach of nomlabofusp to younger patients who experience the most rapid disease progression.

Beyond its lead asset, Larimar is exploring the expansion of its peptide platform into other "loss-of-function" rare diseases characterized by intracellular protein deficiencies. With a strengthened balance sheet and a targeted U.S. commercial launch in the first half of 2027, Larimar is transitioning from a research-heavy biotech into a fully integrated commercial organization. Management’s priority for the remainder of 2026 is the initiation of a global Phase 3 study across the U.S., Europe, and Canada to support full regulatory conversion.

Want more examples? LRGF Covered Calls | LRN Covered Calls